Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Wojciech Feleszko, Ahmad Jalili, Dominika Olszewska, Izabela Mlynarczuk, Tomasz Grzela, Adam Giermasz, Marek Jakóbisiak

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

Original languageEnglish (US)
Pages (from-to)879-885
Number of pages7
JournalOncology Reports
Volume9
Issue number4
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Lovastatin
Cyclooxygenase 2 Inhibitors
Colorectal Neoplasms
Cell Line
Colonic Neoplasms
Apoptosis
Melanoma
Urinary Bladder
Carcinoma
Hydroxymethylglutaryl-CoA Reductase Inhibitors
3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone
Antineoplastic Agents
Colon
Growth

Keywords

  • Apoptosis
  • Colorectal cancer
  • COX-2 inhibitors
  • Lovastatin
  • Synergism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. / Feleszko, Wojciech; Jalili, Ahmad; Olszewska, Dominika; Mlynarczuk, Izabela; Grzela, Tomasz; Giermasz, Adam; Jakóbisiak, Marek.

In: Oncology Reports, Vol. 9, No. 4, 07.2002, p. 879-885.

Research output: Contribution to journalArticle

Feleszko, W, Jalili, A, Olszewska, D, Mlynarczuk, I, Grzela, T, Giermasz, A & Jakóbisiak, M 2002, 'Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines', Oncology Reports, vol. 9, no. 4, pp. 879-885.
Feleszko, Wojciech ; Jalili, Ahmad ; Olszewska, Dominika ; Mlynarczuk, Izabela ; Grzela, Tomasz ; Giermasz, Adam ; Jakóbisiak, Marek. / Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. In: Oncology Reports. 2002 ; Vol. 9, No. 4. pp. 879-885.
@article{181a18a304264436bd508b68a3c4d152,
title = "Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines",
abstract = "Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80{\%} inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.",
keywords = "Apoptosis, Colorectal cancer, COX-2 inhibitors, Lovastatin, Synergism",
author = "Wojciech Feleszko and Ahmad Jalili and Dominika Olszewska and Izabela Mlynarczuk and Tomasz Grzela and Adam Giermasz and Marek Jak{\'o}bisiak",
year = "2002",
month = "7",
language = "English (US)",
volume = "9",
pages = "879--885",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

AU - Feleszko, Wojciech

AU - Jalili, Ahmad

AU - Olszewska, Dominika

AU - Mlynarczuk, Izabela

AU - Grzela, Tomasz

AU - Giermasz, Adam

AU - Jakóbisiak, Marek

PY - 2002/7

Y1 - 2002/7

N2 - Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

AB - Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

KW - Apoptosis

KW - Colorectal cancer

KW - COX-2 inhibitors

KW - Lovastatin

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0036636836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036636836&partnerID=8YFLogxK

M3 - Article

C2 - 12066226

AN - SCOPUS:0036636836

VL - 9

SP - 879

EP - 885

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -